**Supplementary Tables**

**Table S1. Reasons for and type of infection prophylaxis in patients with hypogammaglobulinemia.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Canada** | **France** | **Germany** | **Italy** | **Spain** | **UK** | **USA** | **Pooled** |
| **Number of respondents** | 30 | 30 | 30 | 30 | 30 | 30 | 50 | 230 |
| **Before any infection occurs, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 53 | 47 | 53 | 40 | 47 | 77 | 42 | 51 |
| Antibiotics only | 20 | 33 | 13 | 37 | 27 | 10 | 32 | 25 |
| Both antibiotics and Ig | 13 | 7 | 17 | 3 | 0 | 7 | 6 | 8 |
| Ig only | 13 | 13 | 17 | 20 | 27 | 7 | 20 | 17 |
| Ig total | 27 | 20 | 33 | 23 | 27 | 13 | 26 | 24 |
| **If neutropenia is present, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 37 | 30 | 27 | 20 | 20 | 27 | 14 | 25 |
| Antibiotics only | 30 | 43 | 37 | 43 | 33 | 63 | 44 | 42 |
| Both antibiotics and Ig | 13 | 7 | 27 | 30 | 27 | 7 | 24 | 19 |
| Ig only | 20 | 20 | 10 | 7 | 20 | 3 | 18 | 14 |
| Ig total | 33 | 27 | 37 | 37 | 47 | 10 | 42 | 33 |
| **If vaccination responses against Pneumococcus are insufficient, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 40 | 30 | 47 | 30 | 20 | 20 | 18 | 29 |
| Antibiotics only | 17 | 20 | 20 | 17 | 17 | 47 | 24 | 23 |
| Both antibiotics and Ig | 23 | 10 | 17 | 30 | 33 | 3 | 20 | 20 |
| Ig only | 20 | 40 | 17 | 23 | 30 | 30 | 38 | 28 |
| Ig total | 43 | 50 | 33 | 53 | 63 | 33 | 58 | 48 |
| **After any infection occurs, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 37 | 40 | 33 | 23 | 33 | 53 | 34 | 36 |
| Antibiotics only | 37 | 40 | 20 | 43 | 30 | 37 | 30 | 34 |
| Both antibiotics and Ig | 17 | 10 | 40 | 20 | 17 | 3 | 16 | 18 |
| Ig only | 10 | 10 | 7 | 13 | 20 | 7 | 20 | 12 |
| Ig total | 27 | 20 | 47 | 33 | 37 | 10 | 36 | 30 |
| **After lower respiratory tract infection, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 33 | 10 | 27 | 10 | 33 | 43 | 28 | 26 |
| Antibiotics only | 27 | 43 | 23 | 43 | 33 | 40 | 36 | 35 |
| Both antibiotics and Ig | 20 | 20 | 27 | 27 | 20 | 0 | 14 | 18 |
| Ig only | 20 | 27 | 23 | 20 | 13 | 17 | 22 | 20 |
| Ig total | 40 | 47 | 50 | 47 | 33 | 17 | 36 | 38 |
| **After the first severe infection, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 13 | 10 | 10 | 10 | 10 | 17 | 10 | 11 |
| Antibiotics only | 20 | 27 | 23 | 23 | 13 | 37 | 24 | 24 |
| Both antibiotics and Ig | 33 | 30 | 37 | 40 | 50 | 17 | 42 | 36 |
| Ig only | 33 | 33 | 30 | 27 | 27 | 30 | 24 | 29 |
| Ig total | 67 | 63 | 67 | 67 | 77 | 47 | 66 | 65 |
| **After 2 or more severe infections, %** |  |  |  |  |  |  |  |  |
| No prophylactic treatment | 7 | 0 | 0 | 0 | 3 | 0 | 4 | 2 |
| Antibiotics only | 10 | 7 | 7 | 17 | 7 | 33 | 12 | 13 |
| Both antibiotics and Ig | 63 | 57 | 63 | 57 | 77 | 30 | 70 | 60 |
| Ig only | 20 | 37 | 30 | 27 | 13 | 37 | 14 | 25 |
| Ig total | 83 | 93 | 93 | 83 | 90 | 67 | 84 | 85 |

Ig, immunoglobulin.

**Table S2. Duration of IgG therapy in patients without HSCT**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Canada** | **France** | **Germany** | **Italy** | **Spain** | **UK** | **USA** | **Pooled** |
| **CLL, n** | 21 | 23 | 25 | 24 | 25 | 20 | 35 | 173 |
| Mean (range), months | 13 (2-60) | 12 (3-60) | 13 (2-48) | 7 (1-24) | 10 (3-48) | 17 (2-48) | 10 (2-50) | 12 (1-60) |
| **MM, n** | 19 | 25 | 24 | 22 | 24 | 18 | 31 | 163 |
| Mean (range), months | 11 (3-36) | 12 (3-60) | 12 (2-48) | 6 (1-24) | 10 (3-24) | 14 (1-48) | 10 (2-50) | 10 (1-60) |
| **NHL, n** | 20 | 24 | 25 | 21 | 18 | 19 | 38 | 165 |
| Mean (range), months | 11 (3-24) | 12 (3-60) | 11 (2-48) | 7 (1-24) | 9 (3-15) | 12 (1-48) | 9 (2-50) | 10 (1-60) |
| **Other lymphoproliferative disorders, n** | 16 | 21 | 22 | 18 | 20 | 10 | 36 | 143 |
| Mean (range), months | 15 (3-60) | 12 (2-60) | 13 (2-48) | 6 (1-24) | 10 (2-56) | 10 (2-24) | 8 (2-18) | 10 (1-60) |
| **Total, n** | 23 | 25 | 25 | 27 | 27 | 21 | 43 | 191 |
| **Mean, months** | 12 | 12 | 12 | 7 | 10 | 14 | 9 | 10 |

n, number of respondents